Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lifestyle overhaul may cut dementia risk in latin america

NCT ID NCT06492967

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a structured lifestyle program—including diet, exercise, and cognitive training—can help prevent cognitive decline in older adults at risk for dementia. Over 1,000 participants aged 60-77 from 12 Latin American countries took part. The goal was to see if such a program is feasible and could eventually reduce dementia rates.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lifestyle intervention (diet, exercise, cognitive training, and cardiometabolic risk management)
What this could lead to
If successful, this could show that lifestyle changes can prevent or delay dementia in high-risk older adults, influencing public health policies.
What could go wrong
This is a feasibility study, not a large-scale trial. It measures recruitment and adherence, not whether the intervention actually prevents dementia. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,065 people

The number who actually took part.

Started

Oct 2021

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 77 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age: 60-77 years. * Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score \> 6. * Mini-Mental State Examination (MMSE) z score between 0 and -1.5 OR * CERAD Word List Learning Task (10 word x 3 repetitions) \< 0 z score OR * CERAD (delayed word list recall) \< z score \< 0 Exclusion Criteria * MMSE \< 20 * Dementia * Any medical condition that affects the participant's safety. * Severe osteoarticular problems that preclude the implementation of the physical activity intervention outlined in the protocol, such as, for example: osteoarthrosis of the knee(s), coxofemoral, or other. * Significant neurological disease, including dementia, cognitive impairment, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis or history of significant head injury with persistent neurological sequelae or structural brain abnormalities, major depressive disorder within the last 2 months, history of bipolar disorder or schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders V (DSM V) criteria. * Severe cardiovascular disease, including heart failure, clinically significant aortic stenosis, history of uncontrolled acute myocardial infarction (AMI) or angina and Cardiac rhythm disorders: g3 conduction block, uncontrolled arrhythmia, alterations in Q wave, S waver and T wave segment or QT segment and auricular fibrillation (AF) of less than one year of evolution, venous thrombosis or pulmonary thromboembolism (PTE) of less than 6 months of evolution and any pathology that in clinical judgment compromises the intervention of physical activity. * Body Mass Index \>40 * Cerebral vascular disease in the last 2 years. * Insulin-dependent diabetes mellitus. * Pulmonary disease requiring oxygen and/or steroids. * Renal disease defined as increased renal glomerular filtration rate \<60ml/min/1.73mt2 or albumin excretion rate (AER) \> 30mg/24 hrs. * Clinically significant laboratory abnormalities as judged by the investigator. * History within the last 2 years of treatment for primary or recurrent malignant disease. * History of hip fracture, knee replacement, or spinal surgery within the last 6 months. * Being in cardiopulmonary rehabilitation. * History of bariatric surgery. * Cardiac surgery in the last year. * Severe sensory loss or loss of communication skills. * No schooling. * Use of psychoactive medications within the past 3 months, including tricyclic antidepressants, antipsychotics, psychotropic mood-stabilizing agents (e.g., lithium salts), psychostimulants, opioid analgesics, antiparkinsonian medications, anticonvulsant medications (except gabapentin and pregabalin for non-convulsant indications), systemic corticosteroids, or medications with significant central anticholinergic activity; in the absence of major depression, stable doses of selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors are permitted. * Active participation in another intervention study. * History of alcoholism or substance abuse in the last 2 years, according to DSM V criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Antioquia University

    Antioquia, Colombia

  • Centro Neurológico Mente Activa

    La Paz, Bolivia

  • Clínica de la Memoria - Hospital Británico

    Montevideo, Uruguay

  • Fleni

    Ciudad Autonoma de Buenos Aire, Argentina

  • Hospital Clínica Bíblica

    San José, Costa Rica

  • Hospital Clínico Universidad de Chile

    Santiago, Chile

  • Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez

    Mexico City, Mexico

  • Instituto Peruano de Neurociencas

    Lima, Peru

  • Neuromedicenter - Cognitive Disorders Unit

    Quito, Ecuador

  • Universidad Nacional Pedro Henriquez Urena (UNPHU)

    Santo Domingo, Dominican Republic

  • Universidad de Puerto Rico

    San Juan, Puerto Rico

  • Universidade Federal de Minas Gerais

    Belo Horizonte, Minas Gerais, Brazil

  • University of Sao Paulo School of Medicine

    São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.